Currently Closed – We are no longer accepting or processing applications for new or renewal patients.
The PAN Foundation’s Thyroid Cancer fund is currently closed. As of December 12, 2018, CancerCare’s Metastatic Differentiated Thyroid Cancer fund is accepting applications.
$3,600 per year. Patients may apply for a second grant during their eligibility period subject to availability of funding.
- The patient must be getting treatment for thyroid cancer.
- The patient must have Medicare health insurance that covers his or her qualifying medication or product.
- The patient’s medication or product must be listed on PAN’s list of covered medications.
- The patient’s income must fall at or below 500% of the Federal Poverty Level.
- The patient must reside and receive treatment in the United States or U.S. territories. (U.S. citizenship is not a requirement.)
See the list of medications covered in this program
- Adriamycin (doxorubicin hcl)
- Caprelsa (vandetanib)
- Carboplatin (carboplatin)
- Cometriq (cabozantinib s-malate)
- Dacarbazine (dacarbazine)
- Docefrez (docetaxel)
- Docetaxel (docetaxel)
- Doxorubicin Hcl (doxorubicin hcl)
- Euthyrox (levothyroxine sodium)
- Inlyta (axitinib)
- Lenvima (lenvatinib mesylate)
- Levo-T (levothyroxine sodium)
- Levothyroxine Sodium (levothyroxine sodium)
- Levoxyl (levothyroxine sodium)
- Nexavar (sorafenib tosylate)
- Paclitaxel (paclitaxel)
- Prednisone (prednisone)
- Solu-Medrol (methylprednisolone sodium succinate/pf)
- Sutent (sunitinib malate)
- Synthroid (levothyroxine sodium)
- Taxotere (docetaxel)
- Thyrogen (thyrotropin alfa)
- Tirosint (levothyroxine sodium)
- Unithroid (levothyroxine sodium)
- Vitrakvi (larotrectinib sulfate)
- Votrient (pazopanib hcl)